UB Therapeutics

Dr. Dima Ghannam-Shahbari,

CEO of UB Therapeutics, is a visionary leader with a decade of R&D expertise.

 

Holding a Ph.D. in Medical Sciences from Technion, her research in cancer biology, particularly ovarian cancer, has been widely recognized and published. Dima's extensive knowledge spans genetics, molecular biology, immunology, and advanced microscopy techniques.

 

As a dynamic and dedicated researcher, she has successfully led multiple projects and mentored upcoming scientists, driving UB Therapeutics toward groundbreaking achievements in cancertreatment.

Prof. Ashraf Brik is a world-renowned chemist at the Technion-Israel Institute of
Technology.

 

His groundbreaking research in chemical biology has revolutionized the
understanding of protein modification and ubiquitin signaling, paving the way for
innovative drug discovery. With over 145 publications and numerous prestigious
awards, including the Israel Chemical Society Prize of Excellence and the Advanced ERC Grant, Prof. Brik's work continues to inspire and drive advancements in the
field.

Prof. Peretz Lavie is a distinguished figure in sleep disorder research and a former President of the Technion-Israel Institute of Technology.

 

With a rich history of establishing leading research centers and companies in medical equipment for sleep
testing, Prof. Lavie's expertise and leadership have significantly impacted both academic and industrial spheres.

 

His role as a director on behalf of the Technion brings invaluable strategic guidance and insight to UB Therapeutics, further strengthening our mission to develop groundbreaking treatments.

Sahar Saadi brings a wealth of expertise in biotechnology engineering and
pharmaceutical quality control.

 

With a master's degree in Medical Sciences, Sahar has significant experience in cancer research, particularly in hematological cancers.

Her skills in tissue culture, molecular biology, fluorescence microscopy, and real-time qPCR make her an invaluable asset to our team, contributing to cutting-edge research and innovation in oncology.

Zohar Gindler is a seasoned investor and entrepreneur with an impressive track
record of establishing and investing in over 50 companies.

 

His notable successes include Prolor Biotech (sold to OPKO for $480M), Mazor Robotics (sold to Medtronic for $1.6B), ReWalk (NASDAQ: RWLK), and Corindus (sold to Siemens for $1.1B).
Zohar's extensive experience and strategic vision play a crucial role in guiding UB Therapeutics towards impactful and successful ventures in the biotech industry.

Nizar Mishael, co-founder of NGT Fund I, has over 15 years of experience as CFO
of start-up companies.

 

With hands-on financial expertise from seed investment to early and late financing rounds, Nizar excels in structuring complex investment and
business interactions.

 

His deep understanding of financial and accounting principles, combined with his strategic vision, ensures robust financial management and growth for UB Therapeutics.

Livnat Ben-Zur has over 20 years of executive experience in the medical device and healthcare industries, specializing in management, business development, and marketing.

 

She has led global product development projects and business efforts from design through commercial launch.

​

Previously, Livnat was the CEO of Corolabs and the General Manager of Regentis Biomaterials. She also served as the vice president of Business Development at Galil Medical and held leadership roles at Medinol Ltd. and Datamonitor Inc.